Ann: Trading Halt, page-133

@samfiodiving

Funds raised get ANP to the end of the trial AND the 6 month open label extension (OLE).

I heard SPP will allow shareholders to get some but quite limited. Maybe $2m max. Do the math. Even 500 shareholders means $4k each.

Sam.. you will find my former price targets were a high and low range based on probability. $40 was a 1% chance. My high low was $2 to $40 and that was when we had approx 450m shares on issue. Now we have approx 900m. NEU is the template here as management have stated.

NEU were $250m during recruitment. Hit $500m mkt cap on completion of recruitment. And it hit $1bn mkt cap before results announced. They did have a deal with Acadia and ANP need to do a deal as well to hit those lofty heights pre results. I do think it is a high probability. We will see.

Bullish case - Terminal sales of ATL1102 could be as high as US$8 billion per year assuming a market penetration of 45% of all DMD boys in Europe and USA (20,000 boys out of a possible 44,000) with a sale price of US$400k. Sarepta drugs sell for US$750k. NEU sells for US$300k.

All guess work at the moment but going to be an interesting 12 months.